Montesel Andrea, Sacconi Riccardo, La Rubia Paula, Querques Giuseppe
Moorfields Eye Hospital NHS Foundation Trust, London, UK.
School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Graefes Arch Clin Exp Ophthalmol. 2025 Jan;263(1):235-237. doi: 10.1007/s00417-024-06602-x. Epub 2024 Aug 19.
What is known • Hydroxychloroquine (HCQ) is widely used for autoimmune disorders but is associated with the risk of retinal toxicity. • Early detection of retinal structural changes due to HCQ toxicity remains challenging, and cumulative HCQ dose as a risk factor has conflicting clinical relevance. What Is New • Higher cumulative HCQ doses are significantly associated with thinner outer retinal layers (foveal, parafoveal, and perifoveal regions). • No significant associations were found between HCQ cumulative dose and inner retinal thickness or age.
羟氯喹（HCQ）广泛用于自身免疫性疾病，但存在视网膜毒性风险。
早期检测由HCQ毒性引起的视网膜结构变化仍具有挑战性，且累积HCQ剂量作为风险因素的临床相关性存在争议。
更高的累积HCQ剂量与视网膜外层（黄斑中心凹、黄斑旁中心凹和黄斑周围区域）变薄显著相关。
未发现HCQ累积剂量与视网膜内层厚度或年龄之间存在显著关联。
